Scientists at the European Molecular Biol Laboratory (EMBL) and the University of Heidelberg, Germany, keep come a step closer to kindly how cholesterol levels are regulated. In a glance at published in the journal Cell Metabolism, the researchers identified 20 genes that are involved in this process. Also giving scientists a bigger abstraction of where to look to uncover the mechanisms that lock up cholesterol balance is maintained, the discovery could lead to new treatments for cholesterol-related diseases. "This finding may open original avenues for designing targeted therapies, for condition by looking for minor molecules that could impact these genes, " says Heiko Runz, whose assortment at the University Clinic Heidelberg carried absent the trial well-balanced with Rainer Pepperkok's lab at EMBL. Hovering levels of cholesterol in the bloodstream are a extreme risk factor for atherosclerosis and coronary heart disease, one of the relevant causes of death in developed countries today.
Using a combination of innovative genomic tools, researchers have turned up twenty genes that corner important roles in controlling cholesterol within cells. The findings reported in the The middle of summer 8 question of Cell Metabolism, a Cell Press publication, could end the form to exceptional au courant risk factors for cardiovascular disease, according to the researchers. "High cholesterol in the blood is considered to be responsible for excess cardiovascular morbidity and mortality, " said Heiko Runz of the University of Heidelberg. "Blood cholesterol levels are controlled by cholesterol in cells. Therefore, some of the genes identified by us as regulators of cellular cholesterol in forthcoming studies might turn out to be disease genes that contribute to hypercholesterolemia in some cases. Moreover, the strategy we used could open a modern avenue to identify risk factors for cardiovascular disease." "The factors uncovered may again retain potential as targets for new cholesterol-lowering drugs, " continued Rainer Pepperkok from EMBL Heidelberg, adding that alpine blood cholesterol is a general process that remains difficult to treat.
A recent study published in the Canadian Medical Association Magazine (CMAJ) reports that patients fascinating statins with associated muscle complaints may have structural muscle damage. Whereas of their important role in reducing the risk of cardiovascular disease, statins are one of the most widely prescribed medications worldwide. However, copious patients on statins prosper muscle weakness and pain. In a number of cases, muscle biopsies confirm underlying structural injury, much in patients who complete not show elevated levels of circulating creatine phosphokinase. The study was the elbow grease of researchers from the University of Bern, Switzerland and the Tufts-New Great britain Medical Centre in Boston, Massachusetts. They evaluated muscle biopsies from eighty three patients. Twenty of them had never taken statins. Results showed significant muscle injury in patients who had taken statins, including several who had discontinued medication before the biopsy. Dr. Annette Draeger from the University of Bern and coauthors explain: "Although in clinical practice, the majority of patients with muscle symptoms civilize rapidly after cessation of therapy, our findings device that a subgroup of patients appears to be more susceptible to statin-associated myotoxicity, suffering persistent structural injury.
New research from two Philadelphia-area cardiologists finds that an over-the-counter dietary supplement sold at pharmacies and health food stores may be an alternative for patients who cannot take traditional statin medications to lower cholesterol because of statin-related muscle pain. The findings of their study, "Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients, " check in in the June 16, 2009 issue of Annals of Internal Medicine. Cardiologists David Becker, M.D., and Ram Gordon, M.D., Chestnut Hill Cardiology, studied 62 patients with gigantic cholesterol in the early randomized, double-blinded placebo-controlled research to evaluate brick yeast rice in patients with a chronicle of statin-associated myalgias (side effects that include muscle pain and weakness). Thirty-one of the patients took three 600-mg capsules of burgundy yeast rice twice per day over the succession of six months, and the other half received identical placebo tablets. The red yeast rice patients extremely participated in weekly meetings for the front three months, where they were taught approximately affection disease and how to incorporate heart-healthy nutrition, application and stress state into their lives.
Tekmira Pharmaceuticals Corporation (TSX:TKM) announced that it has initiated a Episode 1 human clinical trial for ApoB SNALP. ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a treatment for patients with elevated low-density lipoprotein (LDL) cholesterol, or "bad" cholesterol, who are not flourishing served by now therapy. ApoB SNALP is designed to reduce the industry of apolipoprotein B (ApoB), a protein produced in the liver that plays a central role in cholesterol metabolism. Dr. Mark J. Murray, Tekmira's President and CEO, said "We are very excited to start the ApoB SNALP Stage 1 clinical trial representing our first RNAi therapeutic clinical analysis and an conspicuous milestone for Tekmira. Our preclinical facts package supports ApoB as an excellent target for LDL cholesterol lowering and we conceive ApoB SNALP is the most latest RNAi therapeutic targeting a metabolic condition. We expect to plentiful the Phase 1 clinical trial in early 2010.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical association focused on the treatment of cardiovascular and metabolic disease, announced ending facts from three separate Chapter II trials involving its cause cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) slender iota drug. The final news was recently presented at the American Diabetes Association's "69th Scientific Sessions" in Contemporary Orleans, LA on June 7, 2009 and the International Symposium on Atherosclerosis (ISA) in Boston, MA on Jun 15, 2009. The three trials ranged in duration from 8 to 12 weeks and collected clinical data on more than 460 patients who suffer from dyslipidemia, a occasion in which there are abnormal levels of lipids in the bloodstream. All three Leaf II trials examined the efficacy, safety and tolerability of lomitapide when administered in low doses, ranging from 2.5mg to 10mg, both alone and in combination with lipid lowering therapies (LLTs) such as Lipitor, Zetia and fenofibrate.
New data presented showed that pitavastatin is an effective treatment for the management of dyslipidemia in elderly patients, with a comparable safety and tolerability profile to low-dose pravastatin. The Phase III data were presented by Kowa, at the XV International Symposium on Atherosclerosis in Boston. "This study shows the effectiveness of pitavastatin to lower LDL [low-density lipoprotein] cholesterol in a battery of antiquated patients with meaningful hypercholesterolemia or combined dyslipidemia, " said Professor Steen Stender, M.D., Ph.D., Gentofte University Hospital, Denmark, and an investigator for the study. "When compared to the regular daily dosage of 40 mg pravastatin, a 4-mg dosage of pitavastatin demonstrated bigger LDL-cholesterol lowering with no expressive safety alteration across all doses, and may buy for a enhanced favourable treatment option for such oppose populations." The Phase III, active-controlled study was conducted for 12 weeks to compare the safety and efficacy of pitavastatin (1 mg, 2 mg and 4 mg) and pravastatin (10 mg, 20 mg and 40 mg) in patients aged amassed than or equal to 65 agedness with primary hypercholesterolemia or combined dyslipidemia.
Calcium Supplementation Has No Weight-loss Cream for Chubby Patients One in three American adults is overweight or obese, with a oppose bulk index (BMI) of 25 or greater. As the obesity percentage continues to rise, researchers seek an road that can prevent weight addition or contribute weight loss. Some studies suggest that people who eat besides dairy products weigh less. Dairy products are a first-class source of calcium. Researchers studied 340 overweight and obese patients to determine if calcium supplementation might prevent weight cush or promote weight loss. The investigators weighed everyone participant and then randomly assigned half of them to returns calcium pills (1500 mg/d) and the other half to placebo. After two years, researchers found no difference in protest weight, BMI, or target fat mass between the two groups. The researchers conclude that while calcium supplementation has health benefits, it is unlikely to prevent weight attainment in overweight or fat patients.
BACKGROUND: Low-density lipoprotein (LDL) is the so-called "bad cholesterol" frequently linked to medical problems adore feelings disease and clogged arteries. Cells in the liver assemble a particular receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs besides reduce LDL cholesterol levels by boosting cells' industry of the receptor. FINDINGS: Using a mouse model, UCLA scientists discovered a new mechanism that controls cells' production of LDL receptor. The foursome identified an enzyme called Idol that destroys the receptor, permitting more LDL cholesterol to circulate in the blood. In blocking Idol's activity, the researchers triggered cells to build extra receptor and absorb more cholesterol from the body. "We apart recognize of three pathways that govern the LDL receptor. The first two are already targeted by existing drugs, " explained Dr. Peter Tontonoz, professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA and an investigator at the Howard Hughes Medical Institute.
A genetic debate from three studies of people living in Denmark get going that those who had higher levels of a cholesterol confessed as lipoprotein (a) due to genetic reasons were at higher risk of love attack. The researchers suggested that although their findings were fixed sufficiently to base the idea that higher levels of lipoprotein (a) due to genetic reasons as well probably cause higher risk of affection attack, by oneself randomized clinical trials that demonstrate fewer passion attacks occur when lipoprotein (a) is reduced through therapy can prove it. The interpret was the work of Dr Pia R Kamstrup, of Herlev Hospital, Copenhagen University Hospital in Herlev, Denmark, and colleagues, and is published in the 10 June issue of the Journal of the American Medical Association, JAMA. In spite of the gospel that statins are now routinely used to lower levels of low-density lipoprotein (LDL, or "bad" cholesterol), myocardial infarction (MI or heart attack) remains a valuable cause of illness and death, wrote the authors.